ADMA Biologics Inc (ADMA)

NASDAQ
1.8950
-0.0350(-1.81%)
  • Volume:
    332,851
  • Day's Range:
    1.8400 - 1.9300
  • 52 wk Range:
    1.0100 - 2.1550

ADMA Overview

Prev. Close
1.93
Day's Range
1.84-1.93
Revenue
93.99M
Open
1.93
52 wk Range
1.01-2.155
EPS
-0.5
Volume
332,851
Market Cap
371.11M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,628,817
P/E Ratio
-
Beta
1.04
1-Year Change
17.68%
Shares Outstanding
196,351,925
Next Earnings Date
Aug 12, 2022
What is your sentiment on ADMA Biologics Inc?
or
Vote to see community's results!

ADMA Biologics Inc News

ADMA Biologics Inc Analysis

ADMA Biologics Inc Company Profile

ADMA Biologics Inc Company Profile

Employees
407

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellSellBuySell
Technical IndicatorsStrong SellStrong SellSellBuyStrong Buy
SummaryStrong SellStrong SellSellBuyNeutral
  • https://www.admabiologics.com/investors/press-releases/detail/521/adma-biologics-reports-record-third-quarter-2021-financial
    0
    • Where is ADMA headed with FDA, down or up?
      0
      • I feel $2.79 resistance then ath by december or feb 22
        0
    • https://finance.yahoo.com/news/adma-biologics-reports-record-second-200500104.html
      0
      • 03/05/2021 13:01 - RSFU.S. RESEARCH ROUNDUP-Federated Hermes, Fidelity National Financial, JetBlue AirwaysMay 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Federated Hermes, Fidelity National Financial and JetBlue Airways, on Monday.....................Adma Biologics Inc : H.C. Wainwright cuts target price to $10 from $11
        1
        • Gaureentee $5 Very Sooon!!! 💰 FDA approval!
          1
          • If you draw anything on its monthly chart, it's going to be a penny stock soon. GLTA
            3
            • Skip7 hours ago I see a lot of people asking how this stock can go down on what seems to be good progress on the revenue and expansion front. Do your homework. Post
              1
              • With the issuance last year (Feb '20 offering) of 27MM common shares combined with the total open market agreement sales (Jefferies) in 2020 of an additional 18.5MM shares plus the 2021 year to date issuance of 16MM shares (Jefferies), this company is dangerously close to maxing out its authorized common shares of 150MM.
                0
              • If they have to seek approval from shareholders to authorize more common shares, or issue "blank check" preferred with no shareholder vote required...dilution will continue to keep this stock headed down...so don't count on any "short squeeze" as a rescue to your long position. I don't have anything negative to say about ADMA's business or management; you just need to look at the capital structure and understand the forces that may be working against you on the long side. Stay safe, be well.
                1
              • Just posted above comments from yahoo ADMA board, and I totally agree with above honest opinions.
                0
            • what? diluted more?! Grossman is insane! we could see it going to $1 soon
              0
              • If it is below $1 and stays, would be pleased to see the reverse split...10X, or 20X... Good luck everyone on the boat!
                0
              • Anyone can tell if Raymond James PT $6 is the price after reverse-split, or not?
                0
            • Executed Commercially with Significant Year-Over-Year Revenue Growth. Achieved full year 2020 total revenues of $42.2 million, compared to $29.3 million for the full year 2019, reflecting a substantial 44% increase. Achieved fourth quarter 2020 total revenues of $14.0 million, compared to $12.0 million for the fourth quarter of 2019, representing an approximately 16% increase.
              1
              • double down at 1.85 1.5 and $1
                0
                • double-down no more, will exit from time to time
                  0